Results 161 to 170 of about 5,310 (212)

Thiopurine S-methyltransferase genotyping among patients with Crohn disease treated with thiopurines

Przegląd Gastroenterologiczny, 2018
openaire  

Some of the next articles are maybe not open access.

Related searches:

Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S‐methyltransferase inhibition

Journal of Gastroenterology and Hepatology, 2021
AbstractBackground and AimThiopurines are often used in combination with mesalazine for the treatment of ulcerative colitis (UC). Mesalazine formulations are delivered to the digestive tract by various delivery systems and absorbed as 5‐aminosalicylic acid (5‐ASA).
Hiromu Morikubo, Taku Kobayashi, Ryo Ozaki, Shinji Okabayashi, Satoshi Kuronuma, Osamu Takeuchi, Tenyo Shiba, Hiroki Kiyohara, Mao Matsubayashi, Shintaro Sagami, Masaru Nakano, Osamu Ikezaki, Tadakazu Hisamatsu, Yoichi Tanaka, Toshifumi Hibi   +14 more
openaire   +2 more sources

Clinical Pharmacogenomics of Thiopurine S-methyltransferase

Current Clinical Pharmacology, 2006
Thiopurine methyltransferase (TPMT) catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine (6-MP), thioguanine and azathioprine (AZA). These drugs are used to treat conditions such as acute lymphoblastic leukemia, inflammatory bowel disease, rheumatoid arthritis, and organ transplant rejection. This review highlights the polymorphisms
Zhou, Shufeng, Brink
openaire   +3 more sources

Clinical Utility of Thiopurine S-Methyltransferase Genotyping

American Journal of PharmacoGenomics, 2004
Thiopurine S-methyltransferase (TPMT) is a cytosolic enzyme that plays a major role in the metabolism of thiopurine drugs such as mercaptopurine and azathioprine. The interindividual differences in response to thiopurine administration is in part due to the presence of genetic polymorphisms in the gene that regulates TPMT activity.
Hèctor, Corominas, Montserrat, Baiget
openaire   +2 more sources

Thiopurine S-methyltransferase pharmacogenetics

Pharmacogenetics, 2003
Thiopurine S-methyltransferase (TPMT) catalyses the S-methylation of thiopurine drugs such as 6-mercaptopurine. A common genetic polymorphism for TPMT is associated with large individual variations in thiopurine drug toxicity and therapeutic efficacy.
Liewei, Wang, William, Sullivan, David, Toft, Richard, Weinshilboum   +3 more
openaire   +2 more sources

Thiopurine S-methyltransferase activity in a Chinese population

Clinical Pharmacology and Therapeutics, 1993
Thiopurine S-methyltransferase is a cytosolic enzyme that catalyzes the S-methylation of thiopurine drugs. Although a genetic polymorphism has been recognized for this enzyme in populations of Caucasian descent, there has been scanty information about this polymorphism among Asians.
Lee, E.J.D., Kalow, W.
openaire   +2 more sources

Clinical relevance of thiopurine S-methyltransferase gene polymorphisms

Neoplasma, 2011
The therapeutic response to thiopurines may result in either severe toxic or inadequate effect based on the interindividual genetic variability. Same drug doses of various anticancer drugs cause considerable interindividual differences in the therapeutic response.
B, Mladosievicova, A, Dzurenkova, S, Sufliarska, A, Carter   +3 more
openaire   +2 more sources

Importance of thiopurine s-methyltransferase gene test

Orvosi Hetilap, 2012
Thiopurine s-methyltransferase enzyme is responsible for the metabolism of immunosuppressant thiopurines, which are used in inflammatory bowel diseases, acute lymphoblastic leukemia and autoimmune diseases. Because of the relative narrow therapeutic index of thiopurines serious or life threatening side effects can occur.
Csilla Sipeky, Anita Maász, Gréta Tarlós, Katalin Komlósi, Éva Pollák, Béla Melegh   +5 more
openaire   +3 more sources